Compass Pathways Adds Biopharma Veteran to Board Ahead of Key FDA Review
Event summary
- Compass Pathways elected Kathleen Tregoning to its Board of Directors on May 28, 2026.
- Tregoning brings extensive biopharma experience, including roles at Cerevel Therapeutics, Sanofi, and Biogen.
- She will serve on the Compensation and Leadership Development Committee and the Nominating and Corporate Governance Committee.
- Compass is currently in the rolling NDA submission and review process for its COMP360 psilocybin treatment.
- Tregoning's expertise in external affairs, public policy, and patient access is seen as critical for Compass's regulatory and commercialization efforts.
The big picture
Compass Pathways is bolstering its governance with a seasoned biopharma executive as it navigates the critical phase of FDA review for its COMP360 psilocybin treatment. Tregoning's background in corporate strategy, external affairs, and patient access is particularly valuable as Compass aims to secure FDA approval and prepare for commercialization. The mental health sector is increasingly focused on innovative treatments, and Compass's progress could set a precedent for the regulatory pathway of psychedelic-assisted therapies.
What we're watching
- Regulatory Strategy
- How Tregoning's expertise will shape Compass's engagement with regulators and payers during the FDA review process.
- Commercialization Readiness
- Whether Compass can effectively transition from clinical-stage to commercial-stage organization if COMP360 receives FDA approval.
- Market Access
- The pace at which Compass can expand education and access for COMP360, given the urgent need for new mental health treatment options.
Related topics